Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 Terminated
55 enrolled
INTEGRAL
Phase 2 Terminated
8 enrolled 10 charts
OTT15-04
Phase 4 Terminated
2 enrolled 4 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Phase 1 Terminated
15 enrolled
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
Terminated
5 enrolled
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Phase 3 Terminated
26 enrolled
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
Phase 2 Terminated
3 enrolled 6 charts
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Phase 2 Terminated
7 enrolled 10 charts
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Phase 1 Terminated
53 enrolled
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Phase 1 Terminated
6 enrolled
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Phase 2 Terminated
33 enrolled
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase 2 Terminated
148 enrolled 9 charts
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Phase 2 Terminated
7 enrolled 8 charts
PREDIXIIHER2
Phase 2 Terminated
6 enrolled
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Phase 4 Terminated
4 enrolled 9 charts
INDUCT
Phase 2 Terminated
66 enrolled 40 charts
BETH
Phase 3 Terminated
3,509 enrolled
AINO
Phase 2 Terminated
65 enrolled
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Phase 1 Terminated
30 enrolled 29 charts
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
31 enrolled 8 charts
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
Phase 1 Terminated
9 enrolled 8 charts
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
Phase 2 Terminated
42 enrolled
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Phase 1/2 Terminated
81 enrolled
STEFNE
Phase 1/2 Terminated
8 enrolled 1 chart
Neohttp
Phase 1/2 Terminated
4 enrolled 1 chart
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Phase 1/2 Terminated
68 enrolled
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase 2 Terminated
23 enrolled 8 charts
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Phase 3 Terminated
49 enrolled 16 charts
NATT
Phase 3 Terminated
102 enrolled
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Phase 2 Terminated
22 enrolled
IXTEND
Phase 2 Terminated
62 enrolled 14 charts
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
Phase 2 Terminated
56 enrolled 16 charts
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Phase 2 Terminated
34 enrolled
MYOHERTAX
Phase 2 Terminated
60 enrolled
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Phase 1/2 Terminated
5 enrolled
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Phase 1 Terminated
54 enrolled
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
Phase 3 Terminated
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Terminated
6 enrolled 5 charts
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Phase 2 Terminated
23 enrolled 7 charts
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Phase 2 Terminated
5 enrolled 6 charts
Docetaxel in Treating Older Women With Metastatic Breast Cancer
Phase 2 Terminated
53 enrolled
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
Phase 2 Terminated
2 enrolled
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
Phase 2 Terminated
25 enrolled
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
Phase 2 Terminated
27 enrolled
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Phase 1 Terminated
38 enrolled
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
Phase 2 Terminated
9 enrolled 7 charts
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Phase 2 Terminated
34 enrolled 9 charts
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Phase 2 Terminated
88 enrolled
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Phase 2 Terminated